Opioid Agonists, Antagonists, and Partial Agonists
Opioid drugs span a spectrum defined by how they act at opioid receptors: full agonists fully activate the receptor and produce dose-dependent analgesia, antagonists block it and can reverse opioid effects, and partial agonists and mixed agonist-antagonists produce submaximal or receptor-selective effects. This classification explains the differing efficacy, ceiling effects, and safety profiles of opioid medications.
Definition
Opioids are classified by their intrinsic activity at opioid receptors: full agonists produce a maximal receptor response, partial agonists produce a submaximal response with a ceiling effect, mixed agonist-antagonists act differently across receptor subtypes, and antagonists bind without activating the receptor and block agonist effects.
Scope
The topic covers the pharmacological classification of opioids by intrinsic activity and receptor selectivity — full agonists, partial agonists, mixed agonist-antagonists, and antagonists — and the concepts of efficacy, potency, and ceiling effect that distinguish them. It is a reference on drug classification, not a prescribing or dosing resource.
Core questions
- How do full agonists, partial agonists, and antagonists differ in their receptor action?
- What is a ceiling effect and why do partial agonists exhibit one?
- How do antagonists reverse or block opioid effects?
- Why do mixed agonist-antagonists have distinctive effect profiles?
Key concepts
- Full agonist
- Partial agonist
- Mixed agonist-antagonist
- Antagonist (competitive blockade)
- Intrinsic activity and efficacy
- Potency vs efficacy
- Ceiling effect
- Receptor selectivity
Mechanisms
An opioid's effect depends on its affinity for opioid receptors and its intrinsic activity once bound. Full agonists evoke the maximal receptor response and produce analgesia that increases with dose; partial agonists bind with high affinity but produce a submaximal response, giving a ceiling effect on both analgesia and respiratory depression. Antagonists occupy the receptor without activating it and competitively displace agonists, which is the basis for reversing opioid overdose. Mixed agonist-antagonists act as agonists at one receptor subtype while blocking another, yielding distinct profiles (Pasternak & Pan, 2013; Brunton et al., 2018). The relationship between receptor engagement and the analgesia-to-harm ratio has motivated efforts to design agonists with biased signaling (Schmid et al., 2017).
Clinical relevance
The agonist-antagonist classification underlies why some opioids have a dose ceiling, why an antagonist can reverse an overdose, and why partial agonists are used in dependence treatment. This entry describes the pharmacological framework for reference and education and does not provide dosing, selection, or reversal protocols, which require current clinical guidance.
History
The agonist-antagonist framework grew from classical receptor theory and the observation that opioids such as morphine, nalorphine, and naloxone produced markedly different effects despite acting on the same receptor system. The identification of distinct receptor subtypes clarified how a single drug could act as agonist at one and antagonist at another, and antagonists became central tools in both research and the management of opioid overdose (Pasternak & Pan, 2013; Brunton et al., 2018).
Key figures
- Gavril Pasternak
- Laura Bohn
Related topics
Seminal works
- pasternak-2013
- goodman-gilman-2018
Frequently asked questions
- What is the difference between a partial agonist and a full agonist?
- A full agonist can produce the receptor's maximal response, so its effects rise with dose, whereas a partial agonist produces only a submaximal response even at full receptor occupancy, giving a ceiling beyond which increasing the dose does not increase the effect.
- How does an opioid antagonist work?
- An antagonist binds the opioid receptor without activating it and competitively displaces agonist molecules, which blocks or reverses opioid effects; this is the pharmacological basis for using antagonists in opioid overdose.